Company Overview and News

217
Nasdaq Composite Closes at Record High: 5 Top-Ranked Picks

2018-06-15 zacks
On Jun 14, the tech-heavy Nasdaq Composite index scaled a fresh high at closing. Yesterday’s rally can be attributed to strong showing by media, telecom and tech stocks fueled by market anticipation of mega merger deals. This also highlights the gradual fading of investors’ apprehensions regarding the trade and geopolitical issues, which was the primary reason behind severe market volatility in the last three months.
FOX DISCB DISCA TWX DISCK TWC CHTR CMTL SPG.PRJ MU MLNX SPG NTAP FOXA DIS DISC

518
20 Long-Term Value Stocks With Hulking Upside

2018-06-14 investorplace
In the value stocks versus growth stocks tug-of-war, growth stocks have been the unequivocal winner for the past several years. But that may change soon.
SIG TIF TWX SKX WMT KR AMZN NKE AAPL DKS KSS KITE INTC DIS GE GEC AMC GILD M TWC FOSL SIG TGT T MU ZUMZ GNE GPS NTAP FL

206
Venture Capital Deals Of The Week: Ant Financial Gets $14B Ahead Of IPO

2018-06-09 seekingalpha
Welcome to Seeking Alpha’s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings.
IBM JD WDC APPN CG CRM HPE GS BABA DVMT ATHM TROW MSFT NTAP

147
Snapchat Focuses on E-commerce Through SeatGeek Integration

2018-06-08 zacks
Snap (SNAP - Free Report) owned Snapchat is evolving into a social platform from a mere photo or video sharing application. The company’s e-commerce strategy is a step toward that direction. Snap has recently teamed up with New York-based event ticket-search engine, SeatGeek that will let users buy tickets to events through Snapchat Stories. Snap has been working on in-app purchases for quite some time now.
FB UNP TWTR NTAP SNAP

204
Top Dividend Raises For May 2018

2018-06-08 seekingalpha
Dividend growth investing is a popular model followed by the investing community to build assets. Companies which not only pay dividends, but raise them year after year have been shown to perform better overall for investor returns.
LRCX CP PAG PSX KGI.DB QBCRF BMO 1128 CP AAPL CAH KL LEG WYNN KGI KGI.DB.A OTEX BMO WYNMF OTC NTAP TU QBCAF WYNMY

77
NetApp: Solid Buy With A 15% Margin Of Safety

2018-06-07 seekingalpha
NetApp is the latest buy for my small portfolio. I replaced my position in Nutanix with the one in NetApp.
NTAP NTNX

30
Fortinet Buys Bradford Networks, Upgrades FortiWeb Software

2018-06-06 zacks
Fortinet Inc. (FTNT - Free Report) recently announced the acquisition of Bradford Networks, a provider of network security by ensuring access control of all devices associated with the enterprise network. The target provides “agentless” surveillance and assessment of end point devices including the ones enabled by Internet of Things (IoT) and caters to multiple industries such as manufacturing, government, retail and technology among others.
TWTR WDC NTAP FTNT

41
Should You Subscribe To Zuora?

2018-06-06 seekingalpha
Another business platform model that's a leader in its field, growing fast and commanding a sky-high valuation.
ZUO SHOP CSCO NTAP CRM ORCL

205
Apple Roundup: WWDC, HomePod, EU Tax, Samsung Infringement

2018-06-05 zacks
With WWDC announcements making headlines, other news gets pushed to the backburner. So here are the highlights from Apple’s (AAPL - Free Report) big event for developers, as well as a brief recap of other events-
EMN.WS GOOGL EMN AAPL NTAP SAM AKAM AZPN

409
5 Top-Ranked Tech Stocks to Buy as Nasdaq Hits Record High

2018-06-05 zacks
On Monday, the Nasdaq hit a fresh record high for the first time in almost three months. A rally in tech and consumer discretionary stocks ensued, indicating that investors are choosing to ignore trade tensions and geopolitical conflicts. Instead, markets are focusing on strong economic fundamentals following last Friday’s strong jobs report.
AMZN NDAQ MU AAPL WDC CTXS STX MSFT NTAP

10
Anatomy of Success: NetApp (NTAP)

2018-06-04 zacks
The Zacks Rank methodology is a unique way to discover some of the best companies to invest in and is a useful tool for beginners and more experienced investors alike; it identifies companies both big and small that have the right characteristics to produce superior gains.
ELY DB NTAP TLRD

5
Is NetApp (NTAP) Stock a Solid Choice Right Now?

2018-06-04 zacks
One stock that might be an intriguing choice for investors right now is NetApp, Inc. (NTAP - Free Report) . This is because this security in the Computer- Storage Devices space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.
DB NTAP MTEM

1
NTAP / NetApp, Inc. SD

2018-05-30 sec.gov
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NTAP

102
Nutanix's Software-Centric Transition Has Significantly More Going For It Than A Missed EPS

2018-05-29 seekingalpha
Despite a single-quarter EPS miss due to added personnel, including sales teams, top-line growth is stronger than ever.
SPLK PANW MS.PRE MS.PRF MS.PRG VMW MS.PRA MS.PRI MS.PRK NTAP MS NTNX

102
Nutanix' Software-Centric Transition Has Significantly More Going For It Than A Missed EPS

2018-05-29 seekingalpha
Despite a single-quarter EPS miss due to added personnel, including sales teams, top-line growth is stronger than ever.
SPLK PANW MS.PRE MS.PRF MS.PRG VMW MS.PRA MS.PRI MS.PRK NTAP MS NTNX

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Silicon Investor Message Boards

This table lists all message boards related to NTAP / NetApp, Inc. on message board site Silicon Investor.

Network Appliance Softechieu0027s KAABBOOOOMM Thread
Club NTAP: Picks for the next year
CUSIP: 64110D104